Promise and pitfalls of new viral biomarkers for hepatocellular carcinoma risk prediction in patients with chronic hepatitis B

References

[1] Polaris Observatory CollaboratorsGlobal prevalence, treatment, and prevention of hepatitis b virus infection in 2016: a modelling study.Lancet Gastroenterol Hepatol2018;3:383-403

[2] Maucort-Boulch D,Franceschi S.Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide.Int J Cancer2018;142:2471-7

[3] Yip TC,Chan HL.HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.J Hepatol2019;70:361-70

[4] Kim GA,Kim MJ.Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.J Hepatol2015;62:1092-9

[5] Desai A,Lai JP.Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review.World J Hepatol2019;11:1-18 PMCID:PMC6354117

[6] Wong VW.Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?.J Hepatol2015;63:722-32

[7] Wang Q,Warren L.Serum hepatitis B surface antigen correlates with tissue covalently closed circular DNA in patients with hepatitis B-associated hepatocellular carcinoma.J Med Virol2016;88:244-51

[8] Kawanaka M,Nakamura J.Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy.Liver Cancer2014;3:41-52 PMCID:PMC3995398

[9] Cheung KS,Wong DK,Yuen MF.Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.J Viral Hepat2017;24:654-61

[10] Mak LY,Wong DK.Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy.J Gastroenterol2021;56:479-88

[11] Liang LY,Toyoda H.Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.J Gastroenterol2020;55:899-908

[12] Tada T,Toyoda H.HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics.J Hepatol2016;65:48-56

[13] Thi Vo T,Charoen P.Association between hepatitis B surface antigen levels and the risk of hepatocellular carcinoma in patients with chronic hepatitis B infection: systematic review and meta-analysis.Asian Pac J Cancer Prev2019;20:2239-46 PMCID:PMC6852811

[14] Yang H,Chan HL.Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.Lancet Oncol2011;12:568-74

[15] Yang HI,Liu J.Incorporating serum level of hepatitis B surface antigen or omitting level of hepatitis B virus DNA does not affect calculation of risk for hepatocellular carcinoma in patients without cirrhosis.Clin Gastroenterol Hepatol2016;14:461-8.e2

[16] Tseng TC,Yang HC.High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.Gastroenterology2012;142:1140-9.e3; quiz e13-4

[17] Tseng TC,Chen CL.Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers.J Infect Dis2013;208:584-93

[18] Suzuki F,Kobayashi M.Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.J Med Virol2009;81:27-33

[19] Testoni B,Scholtes C.Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.J Hepatol2019;70:615-25

[20] Chen S,Gao Y.Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients.Clin Chim Acta2018;486:237-44

[21] Hosaka T,Kobayashi M.Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.Aliment Pharmacol Ther2019;49:457-71

[22] Kumada T,Tada T.Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis.J Hepatol2013;58:427-33

[23] Honda M,Terashima T.Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma.J Infect Dis2016;213:1096-106

[24] Mak LY,To WP.Entecavir reduced serum hepatitis B core-related antigen in chronic hepatitis B patients with hepatocellular carcinoma.Gut Liver2020;14:665-8 PMCID:PMC7492492

[25] Tseng TC,Hsu CY.High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load.Gastroenterology2019;157:1518-29.e3

[26] Tseng TC,Liu CJ.Hepatitis B core-related antigen stratifies the risk of liver cancer in HBeAg-negative patients with indeterminate phase.Am J Gastroenterol2022;

[27] Mak LY,Wong DK.HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy.Hepatology2021;73:2167-79

[28] Liu S,Zhou B.Association of serum hepatitis B virus RNA with hepatocellular carcinoma risk in chronic hepatitis B patients under nucleos(t)ide analogues therapy.J Infect Dis2021;

[29] Liu S,Gu C.Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis.J Natl Cancer Inst2009;101:1066-82 PMCID:PMC2720989

[30] Yang HI,Chen PJ.REVEAL-HBV Study GroupAssociations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.J Natl Cancer Inst2008;100:1134-43 PMCID:PMC2518166

[31] Wei F,Li M.The association between hepatitis B mutants and hepatocellular carcinoma: a meta-analysis.Medicine (Baltimore)2017;96:e6835 PMCID:PMC5428601

[32] Wungu CDK,Prabowo GI,Handajani R.Meta-analysis: association between hepatitis B virus preS mutation and hepatocellular carcinoma risk.J Viral Hepat2021;28:61-71

[33] Liang YJ,Chen CL.Clinical implications of HBV PreS/S mutations and the effects of PreS2 deletion on mitochondria, liver fibrosis, and cancer development.Hepatology2021;74:641-55

[34] Lin YT,Su IJ.Approaches for detection of hepatitis B virus pre-S gene deletions and pre-S deleted proteins and their application in prediction of higher risk of hepatocellular carcinoma development and recurrence.Viruses2022;14:428 PMCID:PMC8877656

[35] Gil-García AI,Francisco-Recuero I.Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.World J Gastroenterol2019;25:5883-96 PMCID:PMC6801187